BOTHELL, WA and VANCOUVER — OncoGenex Pharmaceuticals declared today that OGX-011, also famous as custirsen sodium, conventional Fast Track finding from the U.S. Food & Drug Administration (FDA) in compounding with docetaxel for proportional metastatic endocrine cancer. OGX-011 is currently completing fivesome Phase 2 clinical studies in prostate, lung and boob cancer, and is fashioned to conquer the creation of a limited protein, clusterin, related with communication resistance. Fast Track finding is acknowledged to products that haw wage a momentous transformation in the country or power of the communication for a earnest or life-threatening disease. Based on this designation, the bureau module verify actions as appropri…

Tags: ATM, Breast, breast cancer, Cancer, Current